Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
By F. Hodi, S. O'Day, D. McDermott, R. Weber, J. Sosman, J. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. Hassel and 19 more. New England Journal of Medicine, 2010
14,544 citations recorded by the source corpus.
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response — administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS A total of 676 HLA-A⋆0201–positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival. RESULTS The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P<0.001). The median overall survival with ipilimumab alone was 10.1 months (hazard ratio for death in the comparison with gp100 alone, 0.66; P = 0.003). No difference in overall survival was detected between the ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P = 0.76). Grade 3 or 4 immune-related adverse events occurred in 10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone. There were 14 deaths related to the study drugs (2.1%), and 7 were associated with immune-related adverse events. CONCLUSIONS Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)
Subfields: Immunology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/51d02526aa36effc4d0eedb5649b37a0fbfc57eb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Molecular Biology
In Oncology
Citations in the corpus
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016, background): “IRAEs are frequent; they occur in up to 90% of patients treated with an anti-CTLA-4 antibody [2] and 70% of patients treated with an PD-1/PD-L1 antibody [11,17].”
- Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors (2013, background): “Extensive clinical testing of human blocking anti-CTLA-4 monoclonal antibodies demonstrated an increase in anti-tumor immunity, with approximately 20% of metastatic melanoma patients achieving long-term survival; these substantive clinical benefits resulted in the FDA approval of ipilimumab as first”
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers (2017, background): “Median (range) TMB (mutations/mb) for responders versus nonresponders was 16 (1-58) versus 5 (1-16) (P = 0.”
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (2015, neutral): “Not reported 1 (1) 1 (3) 1 (1) 1 (2) 2 (1)”
- BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma (2013, background): “Food and Drug Administration (FDA)-approved on the basis of positive phase III clinical trial results in advanced melanoma (18) and other immune checkpoint inhibitors in clinical trials.”